Dexcom Inc. (NASDAQ:DXCM) was flying high Friday following a positive panel vote favoring a new indication for its G5 Mobile continuous glucose monitoring (CGM) system. The clinical chemistry and clinical toxicology devices panel of the medical devices advisory committee voted favorably Thursday on the proposed non-adjunctive indication for the mobile CGM system, which would allow it to replace fingerstick glucose testing for diabetes treatment decisions. (See Medical Device Daily, July 22, 2016.)